Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-adjuvant ATRN-119 and SBRT for Early-stage HPV+ OPSCC
NCT07578467Phase 2Not yet recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Jan 2027
- Primary completion
- May 2030
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ATRN-119 in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Abramson Cancer Center. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
ATRN-119
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT07578467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07578467.